Background: The outcome of cancer patients with acute venous thromboembolism (VTE) may differ according to gender. Methods: We used the RIETE database to compare the rate of VTE (pulmonary embolism [PE] or deep vein thrombosis [DVT]) recurrences), major bleeding and mortality during the course of anticoagulation, according to gender. Results: As of August 2014, 11,055 patients with active cancer were enrolled in RIETE, of whom 5,104 (46%) were women. During the course of anticoagulation (mean: 142 days), 505 patients developed recurrent VTE, 429 bled and 2730 died. Compared with men, women had a significantly lower rate of fatal bleeding (risk ratio [RR]: 0.69; 95% CI: 0.47-0.99) and death (RR: 0.90; 95% CI: 0.83-0.97), and a non-significantly lower rate of PE recurrences (RR 0.83; 95% CI: 0.65-1.06) and major bleeding (RR: 0.89; 95% CI: 0.74-1.08). Conclusions: During the course of anticoagulation, cancer women with VTE had a better outcome than men.
Gender differences in cancer patients with acute venous thromboembolism / Martin-Martos, F., Trujillo-Santos, J., Barron, M., Vela, J., Javier Marchena, P., Braester, A., Hij, A., Hernandez-Blasco, L., Verhamme, P., Monreal, M., Pasca, S.. - In: THROMBOSIS RESEARCH. - ISSN 0049-3848. - 135:1(2015), pp. S12-S15. [10.1016/S0049-3848(15)50433-7]
Gender differences in cancer patients with acute venous thromboembolism
Pasca, Samantha
2015-01-01
Abstract
Background: The outcome of cancer patients with acute venous thromboembolism (VTE) may differ according to gender. Methods: We used the RIETE database to compare the rate of VTE (pulmonary embolism [PE] or deep vein thrombosis [DVT]) recurrences), major bleeding and mortality during the course of anticoagulation, according to gender. Results: As of August 2014, 11,055 patients with active cancer were enrolled in RIETE, of whom 5,104 (46%) were women. During the course of anticoagulation (mean: 142 days), 505 patients developed recurrent VTE, 429 bled and 2730 died. Compared with men, women had a significantly lower rate of fatal bleeding (risk ratio [RR]: 0.69; 95% CI: 0.47-0.99) and death (RR: 0.90; 95% CI: 0.83-0.97), and a non-significantly lower rate of PE recurrences (RR 0.83; 95% CI: 0.65-1.06) and major bleeding (RR: 0.89; 95% CI: 0.74-1.08). Conclusions: During the course of anticoagulation, cancer women with VTE had a better outcome than men.| File | Dimensione | Formato | |
|---|---|---|---|
|
S0049-3848(15)50433-7.pdf
Solo gestori archivio
Tipologia:
Versione editoriale (Publisher’s layout)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
397.94 kB
Formato
Adobe PDF
|
397.94 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione



